Conversation with The Cancer LetterCOVID-19 & CancerFree NSCLC patients getting checkpoint inhibitors more likely to develop pneumonitis, Syapse-FDA-Aurora study finds May 01, 2020Vol.46 No.18By Matthew Bin Han Ong
COVID-19 & CancerFree COVID-19 vs. community oncology: Flatiron’s data provides first damage assessment May 01, 2020Vol.46 No.18By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree Tulane Cancer Center chips away at the “digital divide” that keeps the underserved from benefiting from telemedicine April 24, 2020Vol.46 No.17By Alexandria Carolan
Conversation with The Cancer LetterCOVID-19 & CancerFree Feist-Weiller mammography vans repurposed to screen for COVID-19 in northwest Louisiana April 24, 2020Vol.46 No.17By Alexandria Carolan
COVID-19 & CancerFreeGuest Editorial COVID-Lung Cancer Consortium:An example of how the lung cancer community came together in a challenging time April 24, 2020Vol.46 No.17By Fred R. Hirsch, Paul A. Bunn Jr and John D. Minna
COVID-19 & CancerFreeGuest Editorial When disparities widen: COVID-19 in minority patients with cancer April 24, 2020Vol.46 No.17By Coral Olazagasti and Narjust Florez
Conversation with The Cancer LetterCOVID-19 & CancerFree Berry: “Designing clinical trials doesn’t have high priority when there’s no pandemic. And then, when there’s a pandemic, there’s panic” April 24, 2020Vol.46 No.17By Matthew Bin Han Ong
COVID-19 & CancerFree Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19Phase III results for remdesivir expected within weeks April 24, 2020Vol.46 No.17By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening April 22, 2020Vol.46 No.17By Paul Goldberg
Conversation with The Cancer LetterCOVID-19 & CancerFree Lichtenfeld: COVID-19 exposed weaknesses in the U.S. health care system April 17, 2020Vol.46 No.16By Paul Goldberg
